Axsome Therapeutics

Traded on the St. Petersburg Stock Exchange
Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system disorders for which there are limited treatment options.
Axsome Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Axsome Therapeutics balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Axsome Therapeutics cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Axsome Therapeutics multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Axsome Therapeutics profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Axsome Therapeutics assets
Axsome Therapeutics cash flows

Axsome Therapeutics shares

TickerNameTypeNominal valueISINPrice
AXSM:USAxsome Therapeutics, Inc.Common share-US05464T1043$80.66
Axsome Therapeutics news
02.05.2022
Axsome Therapeutics' GAAP loss for 3 months of 2022 was $39.632 million, up 35.5% from $29.259 million in the previous year.
Source: {source} pictogram axsometherapeuticsinc.gcs-web.com
Pictogram next
01.03.2022
Axsome Therapeutics' GAAP loss for 2021 was $130.403 million, up 26.7% from $102.901 million the previous year.
Source: {source} pictogram axsometherapeuticsinc.gcs-web.com
Pictogram next
08.11.2021
Axsome Therapeutics' GAAP loss for 9M 2021 was $96.427 million, up 30.8% from $73.736 million in the prior year.
Source: {source} pictogram axsometherapeuticsinc.gcs-web.com
Pictogram next
09.08.2021
Axsome Therapeutics' GAAP loss for 6M 2021 was $61.544 million, up 21.1% from $50.811 million in the prior year.
Source: {source} pictogram axsometherapeuticsinc.gcs-web.com
Pictogram next
All Axsome Therapeutics news
General information
Company nameAxsome Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241
Mailing address200 BROADWAY, 3RD FLOOR NEW YORK NY 10038
Websitewww.axsome.com
Information disclosurewww.sec.gov